UB Paderborn / Katalog / Suche / in CDI

Epirubicin dose and sequential hormonal therapy—Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer

European journal of cancer (1990), 2016-06, Vol.60, p.146-153

2016

Link zum Volltext

Verfügbarkeit prüfen

33P The multi-switching activity of circulatory neutrophils in patients with early breast cancer

Annals of oncology, 2022-05, Vol.33, p.S137-S138

2022

Link zum Volltext

Verfügbarkeit prüfen

29P The multi-switching activity of circulatory neutrophils in patients with early breast cancer

Annals of oncology, 2021-12, Vol.32, p.S1385

2021

Link zum Volltext

Verfügbarkeit prüfen

26P The multi-switching activity of circulatory neutrophils in patients with early breast cancer

Annals of oncology, 2021-10, Vol.32, p.S1353

2021

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance

Oncogene, 2016-02, Vol.35 (8), p.990-1002

2016

Link zum Volltext

Verfügbarkeit prüfen

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance

Oncogene, 2014-08, Vol.33 (32), p.4144-4155

2014

Link zum Volltext

Verfügbarkeit prüfen

Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group

Journal of clinical oncology, 1999-07, Vol.17 (7), p.1988-1998

1999

Link zum Volltext

Verfügbarkeit prüfen

SUMOylation inhibits FOXM1 activity and delays mitotic transition

Oncogene, 2014-08, Vol.33 (34), p.4316-4329

2014

Link zum Volltext

Verfügbarkeit prüfen

176P Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre

Annals of oncology, 2021-05, Vol.32, p.S94-S94

2021

Link zum Volltext

Verfügbarkeit prüfen

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance

Oncogene, 2010-05, Vol.29 (20), p.2983-2995

2010

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays

Annals of oncology, 2021-08, Vol.32 (8), p.1057-1060

2021

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient

Annals of oncology, 2021-05, Vol.32 (5), p.681-684

2021

Link zum Volltext

Verfügbarkeit prüfen

New IR imaging modalities for cancer detection and for intra-cell chemical mapping with a sub-diffraction mid-IR s-SNOM

Faraday discussions, 2016-01, Vol.187, p.539-553

2016

Link zum Volltext

Verfügbarkeit prüfen

230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

Annals of oncology, 2021-09, Vol.32, p.S458-S458

2021

Link zum Volltext

Verfügbarkeit prüfen

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Annals of oncology, 2021-09, Vol.32, p.S477-S478

2021

Link zum Volltext

Verfügbarkeit prüfen

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Breast cancer research and treatment, 2014-12, Vol.148 (3), p.581-590

2014

Link zum Volltext

Verfügbarkeit prüfen

A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy

Annals of oncology, 2012-04, Vol.23 (4), p.860-866

2012

Link zum Volltext

Verfügbarkeit prüfen

The DEAD-box protein p72 regulates ERα- oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERα-positive breast cancer

Oncogene, 2009-11, Vol.28 (46), p.4053-4064

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

British journal of cancer, 2012-03, Vol.106 (6), p.1062-1067

2012

Link zum Volltext

Verfügbarkeit prüfen

LMTK3 is implicated in endocrine resistance via multiple signaling pathways

Oncogene, 2013-07, Vol.32 (28), p.3371-3380

2013

Link zum Volltext

Verfügbarkeit prüfen

65P Association of the digistain prognostic score with outcomes in patients with HR-positive HER2-negative breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101289, Article 101289

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES

Annals of oncology, 2015-09, Vol.26 (9), p.1890-1897

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen

Annals of oncology, 2010-03, Vol.21 (3), p.498-505

2010

Link zum Volltext

Verfügbarkeit prüfen

The role of genes co-amplified with nicastrin in breast invasive carcinoma

Breast cancer research and treatment, 2014-01, Vol.143 (2), p.393-401

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG

Annals of oncology, 2006-02, Vol.17 (2), p.262-269

2006

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Epirubicin dose and sequential hormonal therapy—Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer

33P The multi-switching activity of circulatory neutrophils in patients with early breast cancer

29P The multi-switching activity of circulatory neutrophils in patients with early breast cancer

26P The multi-switching activity of circulatory neutrophils in patients with early breast cancer

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance

Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group

SUMOylation inhibits FOXM1 activity and delays mitotic transition

176P Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance

Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays

Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient

New IR imaging modalities for cancer detection and for intra-cell chemical mapping with a sub-diffraction mid-IR s-SNOM

230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy

The DEAD-box protein p72 regulates ERα- oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERα-positive breast cancer

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

LMTK3 is implicated in endocrine resistance via multiple signaling pathways

65P Association of the digistain prognostic score with outcomes in patients with HR-positive HER2-negative breast cancer

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen

The role of genes co-amplified with nicastrin in breast invasive carcinoma

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG

Suchergebnisse filtern